Angiotensin II receptor antagonists: Clinical development and future perspectives;ANTAGONISTES DES RECEPTEURS AT1 DE L'ANGIOTENSINE II: DEVELOPPEMENT CLINIQUE ET PERSPECTIVES FUTURES

Therapie

Volumn 53, Issue 3, 1998, Pages 279-284

  Burnier, M ^a   Brunner, H R ^a  

^a Div d'Hypertension Med Vasculaire   (Switzerland)

Author keywords

Angiotensin II antagonists; Heart failure; Humans; Hypertension; Renal

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; TASOSARTAN; TELMISARTAN; VALSARTAN; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; ESSENTIAL HYPERTENSION; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DESIGN; HYPERTENSION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN;

EID: 0032060853     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Eng J Med 1993; 329: 1456-1462.
2. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 23: 1429-1435.
3. Brunner HR, Gavras H, Laragh JH, Keenan R. Angiotensin II blockade in man by Sarl-Ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; ii: 1045-1048
4. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H. Congestive heart failure in normotensive man: haemodynamics, renin, and angiotensin II blockade. Br Heart J 1978; 40: 1134-1142.
5. Burnier M, Brunner HR. Angiotensin II receptor antagonists-antihypertensive agents. Exp Opin Invest Drugs 1997; 6(5): 489-500.
6. Christen Y, Waeber B, Nussberger J et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-1342.
7. Munafo H, Christen Y, Nussberger J et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51 (5): 513-521.
8. Ribstein J, Sissmann J, Picard A et al. Effect of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens 1994, 12 (suppl 3): 131.
9. Steinhauslin F, Buclin T, Bouissou P, Verejan I et al. Angiotensin II (All) blockade effect of ANA-756 in normal volunteers. Clin Pharmacol Ther 1995; 55: 205.
10. Muller P, Cohen T, deGasparo M et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-245.
11. Delacrétaz E, Nussberger J, Biollaz J, Waeber B et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
12. Goldberg MR, Tanaka W, Barchowsky A et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993; 21: 704-713.
13. Burnier M, Hagman M, Nussberger J et al. Short-term and sustained renal effects of angiotesin II receptor blockade in healthy subjects. Hypertension 1995; 25 [part I]: 602-609.
14. Burnier M, Rutschmann B, Nussberger J et al. Salt dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339-347.
15. Schmitt F, Natov S, Martinez F et al Renal effects of angiotensin II receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996; 90: 205-213.
16. Gradham AH, Arcuri KE, Goldberg AI et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
17. Holverda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension-efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14(9): 1147-1151.
18. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54(6): 885-902.
19. Elmfeld D, George M, Hübner R, Olofsson B. Candesartan cilexitil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11(suppl 2): S49-S53.
20. Goldberg A, Dunlay M, Sweet C. The safety and tolerability of losartan potassium, an angiotensin II receptor antagonist in comparison with hydrochlorothiazide, atenolol, felodipine ER and ACE-inhibitors for the treatment of systemic hypertension. Am J Cardiol 75(12): 793-795.
21. Dahlof B, Keller SE, Makris L et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-583.
22. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharm Ther 1996; 60: 341-346.
23. Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 1997; 11 (suppl 2): S91-S95.
24. Soffer BA, Wright JT, Pratt JH et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
25. Phillip T, Letzel H, Arens HJ. Dose-finding of candesartan: study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (suppl 2): S67-S68.
26. Weber MA, Byyny RL, Pratt JH et al. Blood pressure effects of the angiotensin receptor blocker, losartan. Arch Int Med 1995; 155: 405-411.
27. Van den Meiracker AH, Admiraal PJJ, Janssen JA et al. Hemodynamic and biochemical effects of the ATl receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-29.
28. Heuer HJ, Schöndorfer G, Högemann Am. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (suppl 2): S55-S56.
29. Gottlieb SS, Dickstein K, Fleck E et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 8 (part 1): 1602-1609.
30. Crozier I, Ikram H, Awan N et al. for the Losartan Hemodynamic Study Group. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995; 91: 691-697.
31. Dickstein K, Chang P, Willenheimer R et al. Comparison of the effets of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-445.
32. Pitt B, Segal R, Martinez. FA et al. on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
33. Maschio G, Alberti D, Janin G et al. and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
34. Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidnney Int 1994; 45: 861-867.
35. Chan JCN, Critchley JAJH, Tomlinson B et al. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17(1): 72-80.
36. Pohl M, Cooper M, Ulrey J et al. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria. Am J Hypertens 1997; 10: 105A.
37. Lacourcière Y, Brunner H, Irwin R et al and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-1393.
38. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49: 1787-1790.
39. Dahlof B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Human Hypertension 1995; 9 (suppl. 5): S37-S44.
40. Smith RD, Timmermans PBMWM. Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertens 1994; 3: 112-122.
41. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657.
42. 2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98: 418-425.
43. 2 receptor subtypes. Bioorg Med Chem Lett 1994; 4: 2337-2342.